Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479 – March 20, 2023

Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc. today announced that Gilead has exercised its option to exclusively license Nurix’s investigational targeted protein degrader molecule NX‑0479.